Sameeksha Prem
Primary Care · Attleboro, MANPI 1366985160
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,182 of the $1,464 with a category attached, or 80.7%. It is spread thinly across 22 manufacturers, the largest accounting for just 19.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $535 and has fallen 94.6% since, to $29 in 2025.
Across 59 payments — averaging $24.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Astellas Pharma US Inc$283
- Amgen$221
- Incyte Corporation$165
- Johnson & Johnson$158
- AbbVie$102
- Takeda Pharmaceuticals U.S.A., Inc.$72
- plus $464 from 16 others
What the payments were for
- Food & beverage$1,18281%
- Education$28319%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Astellas Pharma US Inc | 4 | $283 |
| Amgen | 11 | $221 |
| Incyte Corporation | 11 | $165 |
| Johnson & Johnson(2 entities) | 3 | $158 |
| AbbVie | 4 | $102 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $72 |
| AstraZeneca | 4 | $70 |
| Gilead | 2 | $45 |
| Genentech USA, Inc. | 2 | $41 |
| Pharmacyclics LLC, An Abbvie Company | 2 | $39 |
| Bayer | 2 | $35 |
| Karyopharm Therapeutics Inc. | 1 | $29 |
| AVEO Pharmaceuticals, Inc. | 1 | $27 |
| Boston Scientific | 1 | $26 |
| Adaptive Biotechnologies Corporation | 1 | $25 |
| Novocure Inc. | 1 | $22 |
| Bristol Myers Squibb | 1 | $21 |
| Novartis | 1 | $20 |
| Acceleron Pharma, Inc. | 1 | $17 |
| Sobi, Inc | 1 | $16 |
| Servier Pharmaceuticals LLC | 1 | $15 |
| Ultragenyx Pharmaceutical Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INVEGA SUSTENNA$125
- INVEGA TRINZA$125
How this compares
$1,464 in reported general payments places this provider in the 85th percentile of 181 primary care providers in Massachusetts.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 78 | $47,383 |
| OzempicSemaglutide | 41 | $41,776 |
| TrulicityDulaglutide | 25 | $25,473 |
| EliquisApixaban | 28 | $16,932 |
| XareltoRivaroxaban | 29 | $16,396 |
| Atorvastatin Calcium | 319 | $16,370 |
| Spiriva RespimatTiotropium Bromide | 24 | $13,558 |
| DapagliflozinDapagliflozin Propanediol | 24 | $13,140 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 19 | $9,679 |
| Incruse ElliptaUmeclidinium Bromide | 19 | $7,257 |
| Tamsulosin Hcl | 129 | $6,285 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 12 | $6,225 |
| MyrbetriqMirabegron | 14 | $6,099 |
| Rosuvastatin Calcium | 75 | $5,705 |
| BrilintaTicagrelor | 12 | $5,433 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $158 | $16,39629 claims |
| Astellas Pharma US IncMyrbetriq | $283 | $6,09914 claims |
| AstraZenecaBrilinta | $70 | $5,43312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 181 primary care providers in Massachusetts.
Other primary care in Attleboro
- Christine HatchNewburyport$11K
- Kate McCabeWinchester$11K
- Alyssa FelverLee$6K
- Katherine WatermanSpringfield$6K
- Joshua AbrahamsFoxborough$6K
- Glynelle WhiteFall River$6K
- Suhaiti VillaLawrence$5K
- Dmitry PrizandBoston$5K
- Ashley KoHaverhill$4K
- Melissa BorgesDartmouth$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.